GGTG Biosciences, Inc.

GGTG Biosciences, Inc. positions itself as the "Angels at the Gate," in contrast to traditional investors. The company distinguishes itself by prioritizing the interests of principal investigators, founders, and executives, aiming to collaborate to bring their visions to life. Notably, the team comprises former academics, drug developers, and company-builders, fostering a patient approach that aligns with the primary motive of principal investigators – to advance their inventions for the benefit of patients. With a committed capital of $10M, GGTG focuses on in-licensing technologies and drug candidates from top academic centers, extending support to emerging startups or mature companies in need of additional funding. The firm tackles high-risk activities that others avoid and invests in biotech companies to gain technology access. GGTG's emphasis on founders, company executives, and patients aims to deliver significant social impact alongside financial returns. The company, headquartered in the United States, was founded in 2022.